Team Approach To Polypharmacy Evaluation And Reduction For General Practice Patients With Dementia: The Australian TAPERdem Study.
Funder
National Health and Medical Research Council
Funding Amount
$586,840.00
Summary
Dementia frequently coexists with other chronic conditions, posing a challenge to optimise medication use. Suboptimal pharmacological management of comorbidities exacerbates the rate of functional decline of PWD. The present study will determine to what extent improved medication management produces better health and functional outcomes for PWD.
Development And Implementation Of Evidence-based Deprescribing Guidelines To Guide Person-centred Care For People With Dementia
Funder
National Health and Medical Research Council
Funding Amount
$623,363.00
Summary
Optimising medication use in people with dementia will include both initiation of necessary medications and withdrawal of unnecessary and harmful medications. Many guidelines exist to aid doctors when prescribing medication, however, no guidelines currently exist that detail when, or how to withdraw medications. Development and implementation of such guidelines into practice may lead to improved quality of life of people with dementia and their carers.
Determining The Clinical Effectiveness Of Antiviral Drugs Against Oseltamivir- And Laninamivir-resistant Influenza Viruses In Animal Models
Funder
National Health and Medical Research Council
Funding Amount
$388,067.00
Summary
Currently, the neuraminidase inhibitors are the only drugs that are effective against seasonal influenza viruses. However, viruses can develop resistance to these drugs. Using viruses with varied levels of resistance, the project will determine the effectiveness of different drug treatments in animal models. This will lead to better treatment for those patients seriously ill with drug-resistant influenza viruses.
The Missing Link: MGluR5 As A Therapeutic Target For Cognitive Decline In Dementia
Funder
National Health and Medical Research Council
Funding Amount
$563,622.00
Summary
Cognitive decline is a core feature of Alzheimer’s Disease (AD), yet there is no cure or treatment. Recent evidence suggests that a protein called mGluR5 could cause brain cells to lose function, leading to memory loss. This project will investigate whether disrupting mGluR5 function can improve cognition in mice with genetic AD. Memory will be assessed in mice using innovative touchscreen tests that closely mimic the tests used in humans.